・FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and expand brilaroxazine’s safety database. ・The company plans to initiate the RECOVER-2 Phase ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) earns a place on our top 10 stocks under $5 that could triple. As of March 19, 2026, 83% of covering analysts maintain bullish ratings for Reviva ...

As of the market open on January 9, 2026, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has surged roughly 37% in 2026 so far, showcasing a strong share price momentum. However, at the same time ...

Fintel reports that on September 23, 2024, EF Hutton initiated coverage of Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) with a Buy recommendation. As of August 26, 2024, the average one-year price ...

The average one-year price target for Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) has been revised to $5.86 / share. This is an increase of 34.17% from the prior estimate of $4.37 dated November 7 ...

) has been revised to $38.15 / share. This is a decrease of 50.79% from the prior estimate of $77.52 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze ...

An announcement from Reviva Pharmaceuticals Holdings ( (RVPH)) is now available. On March 4, 2026, Reviva Pharmaceuticals filed an amendment to its charter to implement a one-for-twenty reverse stock ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is one of the stocks under $1 that will explode. As of the market open on January 9, 2026, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has ...